The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R, S)-ketamine causes rapid onset
and sustained antidepressant actions in treatment-resistant patients with major depressive …

Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for
patients with treatment-resistant depression was a serendipitous finding, clinical use of …

Depression is the most prevalent and among the most debilitating of psychiatric disorders.
The precise neurobiology of this illness is unknown. Several lines of evidence suggest that …

Depression has become one of the most severe psychiatric disorders and endangers the
health of living beings all over the world. In order to explore the molecular mechanism that …

The ventral tegmental area dopamine (VTA-DA) mesolimbic circuit processes emotional,
motivational, and social reward associations together with their more demanding cognitive …

Ketamine, an anesthetic developed in the early 1960s, is also a popular abused drug
among young people at dance parties and raves and among spiritual seekers, because it …

Depression is highly common throughout the life course and dementia is common in late life.
Depression has been linked with dementia, and growing evidence implies that the timing of …

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR)
antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the …